Fig. 1: Mechanism of cytotoxicity mediated by MOv18 IgE. | Nature Communications

Fig. 1: Mechanism of cytotoxicity mediated by MOv18 IgE.

From: Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial

Fig. 1

a The structurally distinct Fc domains of IgE and IgG underpin differences in their biological characteristics, supporting exploration of IgE therapies as potentially superior to IgG [refs. 8,9]. b (1) IgE bound to Fc receptors on macrophages is crosslinked by antigen expressed on tumour cells, leading to target cell cytotoxicity, release of proinflammatory mediators (e.g. TNFα) and macrophage repolarization. (2) TNFα upregulation in turn triggers MCP-1 production by monocytes and tumour cells, followed by (3) recruitment of further macrophages, mediated by MCP-1 [refs. 10,12,14].

Back to article page